Arii Shigeki
Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Nihon Geka Gakkai Zasshi. 2007 Sep;108(5):263-6.
Evidenced-based clinical guidelines for diagnosing and treating hepatocellular carcinoma patients were published in 2005, which were edited by the executive members of the Liver Cancer Study Group of Japan (Chief Editor, Professor Masatosi Makuuchi, MD). This article presents the results of two surveys investigating the validity and usefulness of those guidelines. The author's opinions regarding the evaluation of the guidelines and guideline-based clinical practice are also presented. The surveys revealed that the guidelines are well known and thought to be useful by medical practitioners. The guidelines had changed the therapeutic strategy of 20% of experts in the field. However, 43% of experts and 30% of nonexperts believed that the guidelines restricted their medical discretion. Additionally, the percentage of physicians who felt that medical malpractice suits would increase exceeded those who did not. However, the guidelines do not provide clear recommendations in about 45% of diagnostic and therapeutic points because of a lack of evidence. The recommendations on these points in the guidelines require the commonsense discretion of physicians. The guidelines should be followed based on an understanding of biology and medicine, and not based on dogmatism.
2005年出版了《肝细胞癌患者诊断和治疗的循证临床指南》,由日本肝癌研究组执行成员编辑(主编:牧口正敏教授,医学博士)。本文介绍了两项调查的结果,这两项调查旨在研究这些指南的有效性和实用性。同时也阐述了作者对指南评估以及基于指南的临床实践的看法。调查显示,这些指南广为人知,且被医学从业者认为是有用的。这些指南改变了该领域20%专家的治疗策略。然而,43%的专家和30%的非专家认为这些指南限制了他们的医疗自主权。此外,认为医疗事故诉讼会增加的医生比例超过了持相反看法的医生比例。然而,由于缺乏证据,这些指南在约45%的诊断和治疗要点上并未提供明确建议。指南中关于这些要点的建议需要医生运用常识进行判断。应在理解生物学和医学的基础上遵循这些指南,而不是盲目照搬。